Review of NNRTIs: 'today and tomorrow'

International Journal of Clinical Practice, Supplement

Volumn , Issue 103, 1999, Pages 16-20

  Katlama, Christine ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OXAZINE DERIVATIVE;

CONFERENCE PAPER; DIET; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID METABOLISM; LIPODYSTROPHY; PRIORITY JOURNAL; QUALITY OF LIFE; CLASSIFICATION; CLINICAL TRIAL; DRUG COMBINATION; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; REVIEW;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0032585901     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337: 734-739.
2. Pallela F, Moorman A, Delaney R et al. Dramatically declining morbidity and mortality in an ambulatory HIV-infected population. (Abstract 12343) 12th World Conference, Geneva, June 1998.
3. Brinkman K, ter Hoftede HJM, Burger DM et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-1744.
4. Viramune (nevirapine): Prescribing Information. Boehringer Ingelheim, 1998.
5. Mirochnik M and the ACTG Protocol 250 Team. Safety and pharmacokinetics of nevirapine in neonates born to HIV-1 infected women. (Abstract 533) 4th Conference on Retrovirusees and Opportunistic Infections, Washington, January 1997.
6. Davey RT, Chaitt DG, Reed GF et al. Randomized, controlled Phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type-1-infected patients. Antimicrob Agents Chemother 1996; 40: 1657-1664.
7. Rescriptor Tablets (delavirdine mesylate tablets): Prescribing Information. Pharmacia & Upjohn, 1997.
8. Tashima K, Cu-Uvin S, Callendo A et al. Suppression of viral load in the genital tract and cerebrospinal fluid (CSF) in patients on combination therapy including efavirenz. (Poster 0554) 9th European Conference of Clinical Microbiology and Infectious Diseases, Berlin, March 1999.
9. Workman C, Mussen R and Sullivan J. Salvage therapy using 6 drugs in heavily pretreated patients. (Abstract 426) 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998.
10. Montaner JSG, Reiss P, Cooper S et al. A randomized, double-blind trial comparing combination of nevirapine, didanosine and zidovudine for HIV-infected patients. The INCAS trial. J Am Med Assoc 1998; 279: 930-937.
11. Katlama C, Murphy R, Johnson V et al. The Atlantic Study: a randomized open-label study comparing two protease inhibitors (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen. (Abstract 18) 6th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1999.
12. Riddler S, Kahn J, Hicks C et al. Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for efavirenz (DMP 266) in combination with (IDV) [DMP 266-003, Cohort IV]. (Poster 12359) 12th World AIDS Conference, Geneva, June 1998.
13. Haas DW, Seekins D, Cooper R et al. A Phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, SUSTIVA™, DMP 266) in combination with open-label zidovudine (ZDV) with lamivudine (3TC) at 36 weeks [DMP 266-005]. (Poster 22334) 12th World AIDS Conference, Geneva, June 1998.
14. Staszewski S, Morales-Ramirez J, Tashima K et al. A Phase III, Multicenter, randomized, openlabel study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 24 weeks [DMP 266-006]. (Poster 22336) 12th World AIDS Conference Geneva, June 1998.
15. Fesel WJ, Haas DW, Delapenha RA et al. A Phase III, double-blind, placebo-controlled, multicenter study to determine the effectiveness and tolerability of the combination of efavirenz (EFV, SUSTIVA ™, DMP 266) and indinavir (IDV) versus indinavir in HIV-1 infected patients receiving nucleoside analogue (NRTI) therapy at 24 weeks [DMP 266-020]. (Poster 22343) 12th World AIDS Conference, Geneva, June 1998.
16. Staszewski S, Keiseer P, Gathe E et al. Ziagen/Combivir is equivalent to indinavir/combivir in antiretroviral therapy naïve adults at 24 weeks (CNA3005). (Abstract 20) 6th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1999.